Suppr超能文献

控制药物从大分子前药系统(羧甲基葡聚糖多元醇 - 肽 - 药物缀合物)释放的肽间隔基的系统研究。

Systematic research of peptide spacers controlling drug release from macromolecular prodrug system, carboxymethyldextran polyalcohol-peptide-drug conjugates.

作者信息

Shiose Yoshinobu, Kuga Hiroshi, Ohki Hitoshi, Ikeda Masahiro, Yamashita Fumiyoshi, Hashida Mitsuru

机构信息

Biological Research Laboratories IV and Medicinal Chemistry Research Laboratories II, Daiichi Sankyo Co. Ltd., Kasai R&D Center, Kita-Kasai 1-16-13, Edogawa-Ku, Tokyo 134-8630, Japan.

出版信息

Bioconjug Chem. 2009 Jan;20(1):60-70. doi: 10.1021/bc800238f.

Abstract

The primary purpose of this study was to comprehensively delineate specificity of the peptide spacer sequence to tumor-expressed proteases for the design of macromolecular carrier-peptide spacer-drug conjugate system. 225 conjugates of carboxymethyldextran polyalcohol (CM-Dex-PA) as water-soluble carrier and a dansyl derivative (N-(4-aminobutyl)-5-(dimethylamino)-1-naphthalenesulfonamide, DNS) as the model drug linked with different tetrapeptide spacers (Gly-Gly-P(2)-P(1), P(2), P(1): Ala, Asn, Gly, Cit, Gln, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val) were combinatorially synthesized. First, the drug release assay of all of the fluorogenic model conjugates was performed in murine Meth A solid tumor homogenates. The drug release rate was higher with conjugates having hydrophobic amino acids at P(2). It was also found that conjugates with Asn release the drug rapidly and, in contrast, those with Pro does not. Second, we selected three peptide spacers (Gly-Gly-Phe-Gly, Gly-Gly-Ile-Gly, Gly-Gly-Pro-Leu), which release only DNS at different rates, and applied them to doxorubicin (DXR) conjugates. These three DXR conjugates were used for investigating relationships with drug release, pharmacokinetics, and antitumor activity against Meth A bearing mice of these conjugates. The release of DXR from the conjugates corresponded well with that of DNS conjugates in tumor homogenates. CM-Dex-PA-Gly-Gly-Phe-Gly-DXR and CM-Dex-PA-Gly-Gly-Ile-Gly-DXR indicated strong antitumor activity, with the comparable pharmacokinetic profile of released DXR in tumor. Taken with the fact that the drug release rate in tumor homogenates was approximately 10-fold different between these two DXR conjugates, it is likely that cellular uptake of the conjugate would be rate-limiting, rather than the drug release process under the in vivo situation. However, much weaker antitumor activity was observed with CM-Dex-PA-Gly-Gly-Pro-Leu-DXR, of which the drug release was extremely slow.

摘要

本研究的主要目的是全面描述肽间隔序列对肿瘤表达蛋白酶的特异性,以设计大分子载体 - 肽间隔 - 药物偶联物系统。以羧甲基葡聚糖多元醇(CM - Dex - PA)作为水溶性载体,丹磺酰衍生物(N -(4 - 氨基丁基)- 5 -(二甲基氨基)- 1 - 萘磺酰胺,DNS)作为模型药物,与不同的四肽间隔序列(Gly - Gly - P(2) - P(1),P(2),P(1):丙氨酸、天冬酰胺、甘氨酸、瓜氨酸、谷氨酰胺、异亮氨酸、亮氨酸、甲硫氨酸、苯丙氨酸、脯氨酸、丝氨酸、苏氨酸、色氨酸、酪氨酸和缬氨酸)连接,组合合成了225种偶联物。首先,在小鼠Meth A实体瘤匀浆中对所有荧光模型偶联物进行药物释放测定。P(2)位具有疏水氨基酸的偶联物的药物释放速率更高。还发现天冬酰胺偶联物快速释放药物,相反,脯氨酸偶联物则不释放。其次,我们选择了三种仅以不同速率释放DNS的肽间隔序列(Gly - Gly - 苯丙氨酸 - 甘氨酸、Gly - Gly - 异亮氨酸 - 甘氨酸、Gly - Gly - 脯氨酸 - 亮氨酸),并将它们应用于阿霉素(DXR)偶联物。这三种DXR偶联物用于研究这些偶联物的药物释放、药代动力学以及对荷Meth A小鼠的抗肿瘤活性之间的关系。在肿瘤匀浆中,DXR从偶联物中的释放与DNS偶联物的释放情况良好对应。CM - Dex - PA - Gly - Gly - 苯丙氨酸 - 甘氨酸 - DXR和CM - Dex - PA - Gly - Gly - 异亮氨酸 - 甘氨酸 - DXR显示出较强的抗肿瘤活性,释放的DXR在肿瘤中的药代动力学特征相当。考虑到这两种DXR偶联物在肿瘤匀浆中的药物释放速率相差约10倍,在体内情况下,偶联物的细胞摄取可能是限速步骤,而不是药物释放过程。然而,CM - Dex - PA - Gly - Gly - 脯氨酸 - 亮氨酸 - DXR的抗肿瘤活性要弱得多,其药物释放极其缓慢。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验